Small adjustments can make the difference between short-term success and long-term sustainability
Nathan Seyoum External Medicine Assessor, Ethiopian Food and Drug Authority (EFDA), Ethiopia & Regional Coordinator, East African Regulatory Affairs Professionals Association (EARAPA) Stay tuned for more updates: #AfriSummit #PharmaRegAfriSummit #Regulations #RegulatoryAffairs #Pharmaceutical #Africa To view or add a comment, sign in 17,106 followers More from this author PharmaShots Weekly | Jul 27, 2026 Edition PharmaShots 16h CXO Talks Podcast | Building Smarter Biotech: Venkat Nelabhotla, CEO of Vyome Holdings, on Driving Innovation Across the USIndia Corridor PharmaShots 5d Gona Aziz at HLTH Europe 2026 on the Convergence of AI & 5T MRI: United Imagings Strategy for Advancing Precision Healthcare PharmaShots 1w
the improvement effects of the NPs and MNs treatment groups were not obvious, while the GLP-1RAs@NPs, GLP-1RAs@NPs-WYRGRL and MNs/GLP-1RAs@NPs-WYRGRL groups could effectively alleviate cartilage destruction and osteophyte formation, especially the MNs/GLP-1RAs@NPs-WYRGRL group (Fig
Researchers should note that most indirect comparisons carry the limitations inherent to cross-trial analyses, including differences in baseline populations and trial design
Sandoz, today announces that the US FDA has accepted for review two ANDAs for generic versions of Tirzepatide
Genetic, epidemiological, and clinical research has indicated that lipid abnormalities, such as in low-density lipoprotein cholesterol (LDL-C), are critical factors in the occurrence and progression of CVDs
